Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...

Herbal TB Immunotherapy to be Presented at Hong Kong Conference VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product...

Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial VANCOUVER, British Columbia, Dec. 30, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has published data from the first half of the 120-patient imm01 clinical...

Immunitor Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced...